Journal
TRANSPLANTATION
Volume 107, Issue 2, Pages 351-360Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000004279
Keywords
-
Categories
Ask authors/readers for more resources
Access to kidney transplantation can be facilitated by desensitization strategies targeting HLA-specific sensitization. This review provides an overview of the clinical experience gained in the past 20 years using various tools, including drugs and apheresis options, to achieve desensitization before kidney transplantation.
Access to kidney transplantation is limited by HLA-specific sensitization. Desensitization strategies enable crossmatch-positive kidney transplantation. In this review, we describe clinical experience gained over the last 20 y using desensitization strategies before kidney transplantation and describe the different tools used (both drugs and apheresis options), including IVIg, rituximab, apheresis techniques, interleukin-6 interference, proteasome inhibition, enzymatic degradation of HLA antibodies, complement inhibition, and B cytokine interference. Although access to transplantation for highly sensitized kidney transplantation candidates has been vastly improved by desensitization strategies, it remains, however, limited by the recurrence of HLA antibodies after transplantation and the occurrence of antibody-mediated rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available